HLA-A

HLA class I histocompatibility antigen, A alpha chain · P04439 · HLA-A on Sugi Atlas →

2,764 patent compounds predicted against HLA-A, 2,184 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Astemizole (SCHEMBL4385)	1.00	1/20
Vatalanib (SCHEMBL18286)	1.00	1/20
Raloxifene (SCHEMBL19077)	1.00	1/20
Doxazosin (SCHEMBL42621)	1.00	1/20
Trazodone (SCHEMBL61754)	1.00	1/20
Spiperone (SCHEMBL116031)	1.00	1/20
Doxazosin (SCHEMBL158685)	1.00	1/20
Raloxifene (SCHEMBL178172)	1.00	1/20
Raloxifene (SCHEMBL1665291)	1.00	1/20
Doxazosin (SCHEMBL2945426)	1.00	1/20
Trazodone (SCHEMBL3402550)	1.00	1/20
Doxazosin (SCHEMBL4725733)	1.00	1/20
Raloxifene (SCHEMBL975023)	0.98	1/20
Spiperone (SCHEMBL466892)	0.98	1/20
Trazodone (SCHEMBL28167)	0.98	1/20
Vatalanib (SCHEMBL905598)	0.97	1/20
Vatalanib (SCHEMBL905616)	0.97	1/20
Vatalanib (SCHEMBL6131017)	0.97	1/20
Vatalanib (SCHEMBL6131018)	0.97	1/20
Vatalanib (SCHEMBL6131019)	0.97	1/20

Clinical trials — most relevant to HLA-A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients	PHASE4	COMPLETED
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)	PHASE3	COMPLETED
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation	PHASE3	UNKNOWN
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB	PHASE3	ACTIVE_NOT_RECRUITING
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases	PHASE2	COMPLETED
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Intra Bone Marrow Injection Of Unrelated Cord Blood Cells	PHASE1/PHASE2	UNKNOWN
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System	PHASE1/PHASE2	COMPLETED
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized	PHASE2	NOT_YET_RECRUITING
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT	PHASE1/PHASE2	COMPLETED
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma	PHASE2	COMPLETED
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes	PHASE2	COMPLETED
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer	PHASE2	COMPLETED
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer	PHASE2	WITHDRAWN
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors	PHASE2	COMPLETED
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia	PHASE1	NOT_YET_RECRUITING
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma	PHASE1	COMPLETED
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors	PHASE1	RECRUITING
Dendritic Cell Vaccination During Lymphoid Reconstruction	PHASE1	COMPLETED
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.	EARLY_PHASE1	RECRUITING
The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation	nan	COMPLETED
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers	nan	RECRUITING
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan	nan	RECRUITING
Role of Human Leukocyte Antigen Matching in Liver Transplantation and Its Relation to Outcomes	nan	COMPLETED
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease	nan	RECRUITING
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia	nan	COMPLETED
HLA-DQ in Acute Kidney Transplantation Rejection	nan	COMPLETED
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HLA-A binder may also engage these)

Protein	Name	Similarity
P13749	—	1.000	P13749 →
P13748	—	1.000	P13748 →
P16210	—	1.000	P16210 →
P13747	—	1.000	P13747 →
P01893	—	1.000	P01893 →
P30383	—	1.000	P30383 →
P16209	—	1.000	P16209 →
P30686	—	1.000	P30686 →
P30375	—	1.000	P30375 →
P30387	—	1.000	P30387 →
P13751	—	1.000	P13751 →
P30382	—	1.000	P30382 →
P30379	—	1.000	P30379 →
P06140	—	1.000	P06140 →
P18466	—	1.000	P18466 →
P13752	—	1.000	P13752 →
P16212	—	1.000	P16212 →
P30516	—	1.000	P30516 →
P30388	—	1.000	P30388 →
P14426	—	1.000	P14426 →
P30377	—	1.000	P30377 →
HLA-B	HLA class I histocompatibility antigen, B alpha chain	1.000	landscape →
P16211	—	1.000	P16211 →
P30517	—	1.000	P30517 →
P14427	—	1.000	P14427 →
HLA-C	HLA class I histocompatibility antigen, C alpha chain	1.000	landscape →
P30381	—	1.000	P30381 →
P03991	—	1.000	P03991 →
P01901	—	1.000	P01901 →
P13753	—	1.000	P13753 →